Richard Koya to Molecular Targeted Therapy
This is a "connection" page, showing publications Richard Koya has written about Molecular Targeted Therapy.
Connection Strength
0.066
-
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56.
Score: 0.025
-
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81.
Score: 0.022
-
Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med. 2011 Nov 07; 9:192.
Score: 0.020